Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis

This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs.

Source: Nanomedicine : Nanotechnology, Biology, and Medicine - May 17, 2018 Category: Nanotechnology Authors: B.S. Ling Ding, B.S. Chenfei Zhu, M.S. Fei Yu, M.S. Pengkai Wu, M.S. Gang Chen, B.S. Aftab Ullah, Kaikai Wang, Minjie Sun, Jing Li, David Oupick ý Source Type: research